Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1268929

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1268929

Global Antibacterial Drugs Market - 2023-2030

PUBLISHED:
PAGES: 195 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

The global antibacterial drugs market reached US$ 43,857.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 63,326.8 million by 2030. The global antibacterial drugs market is expected to exhibit a CAGR of 4.8% during the forecast period (2023-2030). Major regional players, such as Shionogi & Co., Ltd., Savior Lifetec, Pfizer Inc., and Spero Therapeutics, among others are focusing the new product launches to increase their sales.

For instance, in February 2023, Japanese pharma firm Shionogi launched an anti-bacterial drug in Denmark. FETCROJA (cefiderocol) is now available in Denmark for treating infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options. This launch in Denmark is an important step in rapidly expanding access to cefiderocol across Europe, where we see an increasing trend in the number of antibiotic-resistant infections enhancing the global antibacterial drugs market.

Antibacterial drugs are derived from bacteria or molds and work by inhibiting cell wall production, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes. Antibacterial drugs, which include phenoxymethylpenicillin and penicillin V, are used to treat bacteria-related disorders. However, it doesn't treat viral infections such as colds, flu, and most coughs.

Furthermore, rising preclinical development pipelines in antibacterial agents, increasing FDA approvals, and increasing partnerships by key market players are the factors that are expected to drive the antibacterial drugs market growth over the forecast period.

Market Dynamics

The increasing collaborations by R&D organizations to address antimicrobial resistance (AMR) drives market growth

According to the Global Antibiotic Research and Development Partnership (GARDP), antibiotic resistance develops when bacteria change over time and no longer respond to treatment. Every year, millions of people suffer from antibiotic resistance, and almost 1.3 million people die. Moreover, the World Health Organisation has identified antibiotic resistance as one of the top ten global health threats and it is spreading globally as a pandemic of drug-resistant infections.

On March 9, 2023, the Global Antibiotic Research and Development Partnership (GARDP) and the University of Liverpool signed a Memorandum of Understanding (MOU) to collaborate on new projects to address antimicrobial resistance (AMR) for the benefit of public health.

Similarly, on April 3, 2023, the World Health Organization and GARDP invited manufacturers to apply to develop cefiderocol, an antibiotic used to treat multidrug-resistant bacterial infections. This is the first time the WHO Prequalification of Medicines Programme (PQP) has included multiple bacterial infections in its work. The PQP has extended an invitation to help initiatives promote the affordability and availability of multidrug-resistant bacteria therapy.

Challenges in developing new antibiotics are hampering the growth of the antibacterial drugs market

Discovering and creating new antibiotics is difficult since the research and development process is time-consuming, costly, and frequently fails. For instance, a new antibiotic can take 10-15 years and more than $1 billion to be developed. Moreover, the final phase of trials and after an initial product launch can account for 80% of the total R&D spend on a new drug, thereby inhibiting the antibacterial drug market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the antibacterial drug market. Hospitals and clinics have delayed or postponed non-emergency appointments, leading to fewer patients receiving proper treatment. Additionally, patients with bacterial infections may have been reluctant to seek medical attention due to fears of contracting COVID-19. As a result, revenue in the antibacterial drugs market has decreased, but they are still used for COVID, ensuring the market's steady growth during the forecast period.

Russia-Ukraine Conflict Analysis

The Ukrainian healthcare system is facing issues due to the Russian invasion, with many facilities destroyed and limited availability due to a shortage of skilled medical staff. According to the national statistics, the invaders have damaged 505 pharmacies in Eastern Ukraine, 47 of which were destroyed, and are blocking humanitarian aid provided by the Ukrainian government or other countries.

Besides, the volume of pharmacy sales doubled in the first 11 days of the Russian invasion due to large amounts of medications purchased by patients with chronic conditions. The top most often bought medicines were antiinflammatory and antirheumatic products, C09, analgesics, psychoanaleptics, diabetes drugs, and antibacterials for systemic use.

The Ukrainian pharmaceutical market has seen a significant drop in sales since March 2022, with 11% in March, 32% in April, and 24% in May and June compared to the same period of 2021. The decline is due to migration, occupation, medical humanitarian aid, and a drop in the income of the population. The downward trend began just after a substantial growth of the market before the war, with 31% in January and 45% in February.

Segment Analysis

The global antibacterial drugs market is segmented based on the action type, drug type, route of administration, drug mechanism, distribution channel, and region.

The oral segment is expected to hold a dominant position in the market over the forecast period.

The oral segment accounted for the highest market stake accounting for approximately 48.8% of the antibacterial drugs market in 2022. Oral administration is the most practical and economical way to administer antibiotics, but it can be unpredictable in certain people. Oral therapy is used when it is tolerable and provides a sufficient therapeutic effect, while parenteral therapy is reserved for patients with difficulty having oral medicines or needing higher antimicrobial activity.

Moreover, oral administration over intravenous administration is beneficial due to the absence of thrombophlebitis and cannula-related infections, reduced drug costs, and decreased hidden costs. It can also make early hospital discharge or discharge straight from the emergency room possible.

For instance, oral antibiotics can treat uncomplicated UTIs, but readmission rates should not be lower than intravenous antibiotics. The bioavailability of oral antibiotics is an important factor in determining the effectiveness of intravenous drugs, as they may be substituted depending on the condition and drug penetration. Antibiotics such as Clindamycin, Fluconazole, Metronidazole, Sulfamethoxazole/trimethoprim, and Doxycline are commonly administered orally. Therefore, this segment will boost the global antibacterial drugs market growth over the forecast period.

Geographical Analysis

The merger and acquisition strategy by the key market players is to dominate the North American region.

North America is expected to dominate the worldwide antibacterial drugs market, accounting for around 1/3rd of this market, with the U.S. being the major contributor. For instance, in May 2022, Entasis Therapeutics, an antibiotic biotech, was acquired by Innoviva. On a fully diluted basis, the transaction values Entasis' stock at $113 million. Entasis' flagship medicine, SUL-DUR, outperformed an existing treatment in phase 3 clinical trial last year and is scheduled for FDA approval in mid-2022. SUL-DUR is a targeted antibiotic.

Competitive Landscape

The major global players in the market include: Pfizer Inc., Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Shionogi & Co., Ltd., Eli Lilly and Company, GlaxoSmithKline Plc, Bristol Myers Squibb Company, and Novartis AG, among others.

Why Purchase the Report?

  • To visualize the global antibacterial drugs market segmentation based on the action type, drug type, route of administration, drug mechanism, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of antibacterial drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global antibacterial drugs market report would provide approximately 77 tables, 76 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Product Code: PH1511

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Action Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Drug Mechanism
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing collaborations by R&D organizations to address antimicrobial resistance (AMR) drives market growth
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges in developing new antibiotics are hampering the growth of the antibacterial drugs market
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing number of clinical trials
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Action Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 8.1.2. Market Attractiveness Index, By Action Type
  • 8.2. Bacteriostatic*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Bactericidal

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Beta-lactams*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Aminoglycosides
  • 9.4. Macrolides
  • 9.5. Quinolones
  • 9.6. Tetracyclines
  • 9.7. Sulfonamide
  • 9.8. Others

10. By Route of Administration

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Oral*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Parenteral
  • 10.4. Others

11. By Drug Mechanism

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 11.1.2. Market Attractiveness Index, By Drug Mechanism
  • 11.2. Inhibition of Cell Wall Synthesis*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Inhibition of Protein Synthesis
  • 11.4. Alteration of Cell Membranes
  • 11.5. Inhibition of Nucleic Acid Synthesis
  • 11.6. Antimetabolite Activity

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Retail Pharmacies*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Hospital Pharmacies
  • 12.4. Online Pharmacies

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.8.1. The U.S.
      • 13.2.8.2. Canada
      • 13.2.8.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.8.1. Germany
      • 13.3.8.2. The U.K.
      • 13.3.8.3. France
      • 13.3.8.4. Italy
      • 13.3.8.5. Spain
      • 13.3.8.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.8.1. Brazil
      • 13.4.8.2. Argentina
      • 13.4.8.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.8.1. China
      • 13.5.8.2. India
      • 13.5.8.3. Japan
      • 13.5.8.4. Australia
      • 13.5.8.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Pfizer Inc.*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Sanofi S.A.
  • 15.3. Bayer AG
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Dr. Reddy's Laboratories Ltd.
  • 15.6. Novartis AG
  • 15.7. Bristol Myers Squibb Company
  • 15.8. GlaxoSmithKline Plc
  • 15.9. Eli Lilly and Company
  • 15.10. Shionogi & Co., Ltd.

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!